Distinct methylation profiles of glioma subtypes

International Journal of Cancer

Volumn 106, Issue 1, 2003, Pages 52-59

  Uhlmann, Karen ^a,b   Rohde, Klaus ^b   Zeller, Constanze ^a,b   Szymas, Janusz ^c   Vogel, Siegfried ^d   Marczinek, Karola ^a   Thiel, Gundula ^a   Nürnberg, Peter ^a,b,f   Laird, Peter W ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Katedra Patomorfologii Kliniczney   (Poland)

^d Sankt Gertrauden Krankenhaus   (Germany)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f Gene Mapping Center   (Germany)

Author keywords

DNA methylation; Gliomas; Hypermethylation; Hypomethylation; Methylation profiles; Pilocytic astrocytomas

Indexed keywords

APC PROTEIN; ARF PROTEIN; BISULFITE; DNA; MYOD1 PROTEIN; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CHILD; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PHENOTYPE; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CPG ISLANDS; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; INFANT; MALE; METHYLATION; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; SULFITES;

EID: 0037531563     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11175     Document Type: Article

References (27)

1. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet 2000;1:11-9.
2. Baylin SB, Herman JG, Graff JR, Vertino PM. Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
3. Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet 1998;20:116-7.
4. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
5. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
6. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
7. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
8. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
9. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
10. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
11. Russel DS, Rubinstein LJ. Pathology of tumors of the nervous system. Baltimore: Williams and Wilkins, 1989. p. 124-125.
12. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887.
13. Costello JF, Berger MS, Huang HS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-10.
14. Li Q, Jedlicka A, Ahuja N, Gibbons MC, Baylin SB, Burger PC, Issa JP. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 1998;16:3197-202.
15. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
16. Costello JF, Plass C, Cavenee WK. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol 2000;17:49-56.
17. Uhlmann K, Marczinek K, Hampe J, Thiel G, Nurnberg P. Changes in methylation patterns identified by two-dimensional DNA fingerprinting. Electrophoresis 1999;20:1748-55.
18. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
19. Marczinek K, Hampe J, Uhlmann K, Thiel G, Barth I, Mrowka R, Vogel S, Nurnberg P. Genomic difference analysis by two-dimensional DNA fingerprinting reveals typical changes in human low-grade gliomas. Glia 1998;23:130-8.
20. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996;24:5064-6.
21. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60:5021-6.
22. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722-7.
23. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-9.
24. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19:3816-22.
25. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993;8:1063-7.
26. Schwechheimer K, Zhou L, Birchmeier WE. Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas. Virchows Arch 1998;432:163-7.
27. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-02.